Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US
NCT03537508
Completed
The purpose of this study was to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the US.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
10/10/2024
Locations: Birmingham Pediatric Associates Site Number : 8400026, Birmingham, Alabama +69 locations
Conditions: Healthy Volunteers (Meningococcal Infection)
Register for Updates
High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant
NCT02860039
Completed
This phase II randomized trial studies how well high dose flu vaccine works in treating children who have undergone done stem cell transplant. Higher dose flu vaccine may build a better immune response and may provide better protection against the flu than the standard vaccine.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
10/10/2024
Locations: UCSF Children's Hospital, San Francisco, California +8 locations
Conditions: Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
Register for Updates
A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
NCT06361875
Active Not Recruiting
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Long Beach Clinical Trials Site Number : 8400013, Long Beach, California +19 locations
Conditions: Influenza Immunization
Register for Updates
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
NCT06172660
Recruiting
The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice. Some of the questions that the investigators hope to answer with this study are: 1) What is the overall effectiveness of these vaccines? 2) How long does immunity last? 3) How effective are the vaccines against new strains? 3) Does the vaccine's effectiveness vary by age?
Gender:
ALL
Ages:
12 months and below
Trial Updated:
10/03/2024
Locations: Yale Child Health Research Center, New Haven, Connecticut
Conditions: RSV Infection
Register for Updates
Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study
NCT06503900
Recruiting
This study is a prospective, randomized clinical trial. During this study,pregnant participants will be randomly assigned to receive IIV and mRNA COVID-19 vaccine either simultaneously or sequentially (7-14 days apart). All participants will receive an mRNA COVID-19 vaccine at Visit 1 (Day 1). Solicited local and systemic symptoms of reactogenicity will be assessed on day of visit for Visits 1 and 2 and daily during the 6 days following each visit using either electronic or paper symptoms diari... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: Emory University, Atlanta, Georgia +5 locations
Conditions: Birth Outcomes, Safety, Adverse Event Following Immunization
Register for Updates
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
NCT03354728
Recruiting
This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vaccinia ankara vaccine may help people resist CMV life-threatening complications.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
10/01/2024
Locations: City of Hope Medical Center, Duarte, California
Conditions: Cytomegaloviral Infection, Hematopoietic Cell Transplant Recipient
Register for Updates
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
NCT04917861
Completed
This clinical study will evaluate the safety, tolerability, and reactogenicity of 2 dose levels of messenger RNA (mRNA)-1893 Zika vaccine in comparison to a placebo control in healthy participants who are flavivirus-seronegative and in participants who are flavivirus-seropositive.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
09/27/2024
Locations: Meridian Clinical Research (Sioux City, IA), Sioux City, Iowa +10 locations
Conditions: Zika Virus
Register for Updates
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults
NCT05297578
Completed
The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 65 years of age and older.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/26/2024
Locations: Accel Research Sites-Birmingham Clinical Research Unit, Birmingham, Alabama +19 locations
Conditions: Pneumococcal Vaccines
Register for Updates
COVID-19 Protection After Transplant Pilot Study
NCT04969263
Completed
Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who have higher antibody levels. What level of antibodies is necessary for protection is currently unknown. Inadequate antibody response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination has been described among kidney transplant recipients. The aim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Kidney Transplant Recipients
Register for Updates
H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
NCT02921997
Completed
This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years old, inclusive, designed to evaluate and compare the immunogenicity between an intramuscular monovalent inactivated influenza A/H7N9 virus vaccine given with and without AS03 adjuvant, and an intramuscular unadjuvanted monovalent inactivated influenza A/H3N2v virus vaccine. The primary objectives are (1) assessi... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
09/26/2024
Locations: Vanderbilt University Medical Center - Vanderbilt Institute for Clinical and Translational Research - Clinical Research Center (VICTR-CRC), Nashville, Tennessee
Conditions: Avian Influenza, H1N1 Influenza, Influenza
Register for Updates
Vaccine Responses in Cancer
NCT06605625
Recruiting
The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.
Gender:
ALL
Ages:
All
Trial Updated:
09/25/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Viral Vaccines
Register for Updates
A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults
NCT05518500
Recruiting
This is a prospective, single-arm study designed to understand the mechanisms that lead to a loss of response to influenza vaccine in older adults. The investigators will recruit and longitudinally follow a cohort of 75 older adults (65 years and older) who will receive three different influenza vaccines over three annual influenza seasons. Blood samples will be collected from the participants at sixteen study visits over three years. Nasal swab and stool samples will also be collected from part... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
09/17/2024
Locations: UConn Health, Center On Aging, Farmington, Connecticut
Conditions: Aging, Influenza Vaccine, Dendritic Cell, Vaccine Response
Register for Updates